RT Journal Article
T1 Supraequatorial displacement with lateral rectus myopexy for treatment of myopic sagging/heavy eye
A1 Merino, Pilar
A1 Antón, Vlad
A1 Chamorro, Mattheus
A1 Gómez De Liaño Sánchez, Pilar
A1 Yáñez Merino, Jacobo
AB Purpose: To describe the outcome of the patients diagnosed of sagging/heavy eye associated to myopia, that were operated on with the supra-equatorial displacement with LR myopexy.Methods: A retrospective study of 9 cases between 2017-2023. The following data were analyzed: horizontal and vertical deviation, diplopia, amblyopia, ductions, ocular torsion, sensorial test, macular pathology, and the orbital magnetic resonance. Treatment was considered Successful if the diplopia was improved or eliminated and a final vertical deviation (VD) ≤5 prism diopters (PD).Results: The mean age (SD) was: 62.11 (4.6) years (100% women). A total of 88.88% presented diplopia. The mean preoperative hypotropia was: 11.33 PD (SD 3.16), and the mean final VD 3.44 PD (SD 3.05). After surgery, the hypotropia was overcorrected in one case, under corrected in 5, and orthophoria was achieved in another three. The technique was associated with surgery of another rectus muscle in 4 subjects. The mean follow-up time after surgery was 34 months (SD 34.62). Six of the 9 patients improved with a vertical deviation ≤5 PD. In 3 patients, the diplopia was eliminated, while in 5 it remained intermittent (three with macular pathology).Conclusion: Supra-equatorial displacement with LR myopexy for treatment of myopic sagging/heavy eye, is a therapeutic option if hypotropia is less than 12 PD or the Yokoyama technique is not indicated. A good result was obtained in most cases, although diplopia could only be totally suppressed in three, and another five remained intermittent.
PB Elsevier
SN 0365-6691
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/92513
UL https://hdl.handle.net/20.500.14352/92513
LA eng
NO Merino P, et al. Supraequatorial displacement with lateral rectus myopexy for treatment of myopic sagging/heavy eye. Arch Soc Esp Oftalmol. 2023.
DS Docta Complutense
RD 10 abr 2025